India’s biotechnology sector is one of the most strategically important and rapidly evolving segments of the country’s economy, with the biotech economy growing from USD 10 billion in 2015 to USD 130 billion in 2024 and expected to reach USD 150 billion in 2025. India’s bio-economy is projected to reach Rs 92.44 lakh crore or USD 1 trillion by 2047, driven by rapid biotech growth and policy support. India accounts for approximately 4 percent of the global biotech market and produces 65 percent of the WHO’s vaccine requirements globally, manufacturing 60 percent of global DPT, BCG, and measles vaccines. Based on market capitalisation as of May 11, 2026, the biggest biotech company in India is Biocon Limited. India is advancing its biopharmaceutical ambitions through the Biopharma SHAKTI initiative which aims to launch 100 biologics by 2047, and there are currently 12 DBT-supported biotechnology parks and 73 BIRAC-supported bio-incubators across the country. Let us have a look at the top 10 biotech companies in India for the year 2026.
1. Biocon Limited
Biocon Limited, founded in the year 1978 by Kiran Mazumdar-Shaw in Bengaluru and the largest biotech company in India by market capitalisation as of May 11, 2026, is a fully integrated innovation-led biopharmaceutical company with products reaching over 120 countries, employing more than 16,300 professionals, and holding over 1,500 patents granted alongside over 1,025 registered trademarks. The company won the National IP Award 2024 and was named among Asia IP Elite 2024, and its biosimilar subsidiary Biocon Biologics has achieved landmark commercial success including Insulin Glargine Semglee becoming the world’s first interchangeable biosimilar. Biocon operates in generics, biosimilars, research services, and novel biologics.
Biocon serves the global healthcare market with its affordable biopharmaceuticals for diabetes, cancer, and autoimmune diseases through its four global business divisions, and its integrated model from discovery through manufacturing to commercialisation enables it to compete with global biopharmaceutical companies on both price and clinical quality.
2. Serum Institute of India Private Limited
Serum Institute of India, founded in the year 1966 by Dr. Cyrus S. Poonawalla and headquartered in Pune as a subsidiary of the Poonawalla Group, is the world’s largest vaccine manufacturer by volume, supplying life-saving vaccines to over 170 countries and immunising nearly 65 percent of the world’s children with at least one SII vaccine. The company delivers 1.5 billion plus vaccine doses annually including COVISHIELD, MMR, DTP, and essential vaccines, with COVISHIELD developed in partnership with Oxford University and AstraZeneca becoming one of the most widely used COVID-19 vaccines worldwide. SII has an estimated market value of Rs 1.92 lakh crore making it the most valuable unlisted company in India.
Serum Institute serves the global public health community with its massive-scale affordable vaccine manufacturing, and its status as the world’s largest vaccine manufacturer by volume combined with WHO prequalified production facilities makes it the single most important institution in global vaccine supply security for developing nations.
3. Bharat Biotech International Limited
Bharat Biotech International, headquartered in Hyderabad and founded in the year 1996 by Dr. Krishna Ella, is one of India’s most innovative vaccine and biotherapeutics companies known for developing COVAXIN — India’s first indigenous COVID-19 vaccine — alongside a comprehensive portfolio of vaccines for rotavirus, typhoid, rabies, Zika, chikungunya, and other infectious diseases. The company announced successful Phase 3 trials for its chikungunya vaccine in November 2023, a groundbreaking indigenous vaccine for preventing a mosquito-borne viral infection prevalent in India and tropical regions globally.
Bharat Biotech serves the global vaccine market with its innovative vaccine portfolio and is one of the few companies in the world with end-to-end vaccine development capability from discovery through large-scale manufacturing, and its COVAXIN development demonstrated India’s capacity to develop and manufacture globally distributed vaccines for pandemic response.
4. Dr. Reddy’s Laboratories Limited
Dr. Reddy’s Laboratories, established in the year 1984 by K. Anji Reddy and headquartered in Hyderabad, is one of India’s largest integrated pharmaceutical and biotech companies with a strong biosimilars pipeline and presence in regulated markets across the United States, Europe, and emerging markets. The company is cited among India’s key biotech players for its biosimilar portfolio and novel drug development programs, and its extensive regulatory track record with USFDA, EMA, and other agencies makes it one of the most globally compliance-capable pharmaceutical biotech companies in India.
Dr. Reddy’s serves patients globally with its generics, biosimilars, and innovative pharmaceutical products, and is a leader in the biosimilars market given its regulatory expertise across multiple global markets that enables it to navigate the complex approval pathways required to commercialise biosimilar versions of branded biologic medicines.
5. Zydus Lifesciences Limited
Zydus Lifesciences, formerly Cadila Healthcare and founded in the year 1952 and headquartered in Ahmedabad, is one of India’s leading biopharmaceutical companies with a strong biosimilars and novel biologics pipeline including the world’s first approval for its DNA plasmid COVID-19 vaccine ZyCoV-D. The company is cited among India’s major biotechnology players for its innovative research capabilities and its growing biologics portfolio spanning oncology, diabetes, and immunology therapeutic areas.
Zydus Lifesciences serves patients across India and internationally with its growing biologics and biosimilar portfolio alongside its established generics business, and its ZyCoV-D vaccine achievement as the world’s first approved DNA-based vaccine represents a landmark in India’s innovation-led biotechnology capabilities.
6. Panacea Biotec Limited
Panacea Biotec, founded in the year 1984 and an innovation-driven biotechnology company engaged in research, development, manufacturing, and global distribution of pharmaceuticals and vaccines, has USFDA-approved facilities in Baddi and WHO-prequalified vaccine units in Lalru and Baddi. The company expanded into 30 plus global markets with major innovations including EasyFive, the world’s first fully liquid pentavalent vaccine, and EasySix, the first fully liquid wP-IPV hexavalent vaccine.
Panacea Biotec serves the global paediatric vaccine market with its innovative combination vaccine products that simplify immunisation schedules in developing countries, and its WHO prequalified manufacturing facilities and global regulatory approvals position it as an important player in the global childhood immunisation program alongside Serum Institute.
7. Bharat Serums and Vaccines Limited
Bharat Serums and Vaccines Limited, established in the year 1971 and headquartered in Mumbai, is one of India’s leading biopharmaceutical companies with breakthrough innovations including India’s first High-Pure HMG, recombinant FSH and HCG, and novel drug delivery formulations like liposomal Amphotericin B. Globally, BSV is the first to develop Anti-Rh(D) Monoclonal Antibody, Monoclonal Tetanus, and Amphotericin B Emulsion for NDDS applications, with particularly strong specialisation in complex, hard-to-manufacture biologics serving nephrology, critical care, and haematology.
Bharat Serums and Vaccines serves hospitals and healthcare professionals in complex critical care specialties with its biopharmaceutical products, and its portfolio of first-in-class developments in reproductive medicine, haematology, and critical care biologics positions it as one of India’s most technically innovative biopharmaceutical companies despite operating at a smaller scale than Biocon or Serum Institute.
8. Syngene International Limited
Syngene International, established in the year 1993 as a part of Biocon and headquartered in Bengaluru, is a leading Contract Research, Development, and Manufacturing Organisation that offers integrated services across the drug development value chain including discovery chemistry, biology, safety assessment, and commercial manufacturing for global pharmaceutical, biotechnology, and agrochemical companies. The company opened a new biologics manufacturing facility in Bangalore in November 2025 designed to meet USFDA standards for monoclonal antibody production, positioning India as a high-quality hub for complex biologic outsourcing.
Syngene serves global pharmaceutical and biotech companies with its end-to-end contract research and manufacturing services, and its client relationships with companies including Bristol-Myers Squibb, GSK, and Amgen reflect the confidence that world-class global pharmaceutical companies have in India’s ability to conduct complex drug development and manufacturing under international quality standards.
9. Gennova Biopharmaceuticals Limited
Gennova Biopharmaceuticals, a subsidiary of Emcure Pharmaceuticals and headquartered in Pune, gained global recognition through the development of India’s first mRNA-based COVID-19 vaccine and has positioned itself at the forefront of next-generation vaccine platforms. The company’s mRNA vaccine development capability represents one of India’s most significant advances into cutting-edge biotechnology platforms that were previously dominated entirely by Western and Chinese pharmaceutical companies.
Gennova Biopharmaceuticals serves the next-generation vaccine market with its pioneering mRNA technology platform, and its successful mRNA vaccine development represents a breakthrough in India’s biotechnology capability that positions it for leadership in RNA-based therapeutics and vaccines that are expected to be the defining modality of next-generation biopharmaceuticals.
10. Indian Immunologicals Limited
Indian Immunologicals Limited, established in the year 1982 by the National Dairy Development Board and headquartered in Hyderabad, is a government-backed biotechnology company focused on vaccines and biologicals for human and animal health applications. The company produces rabies vaccines, hepatitis vaccines, and veterinary biologicals with WHO prequalified manufacturing facilities, and is an important player in India’s vaccine manufacturing ecosystem particularly for the animal health and agricultural biotechnology segments.
Indian Immunologicals serves both human health and animal health vaccine markets with its government-backed manufacturing capabilities, and its unique position as an NDDB subsidiary gives it a distinctive mandate in supporting India’s agricultural sector through animal disease vaccines alongside its more commercially competitive human health vaccine portfolio.
Frequently Asked Questions (FAQs)
Q: Which is the largest biotech company in India in 2026?
A: Based on market capitalisation as of May 11, 2026, Biocon Limited is the largest biotech company in India. By revenue and global operational scale, Serum Institute of India — the world’s largest vaccine manufacturer by volume — is arguably the most impactful Indian biotech company globally, with an estimated market value of Rs 1.92 lakh crore making it the most valuable unlisted company in India.
Q: What is the size of India’s biotech market in 2026?
A: India’s bio-economy grew from USD 10 billion in 2015 to USD 130 billion in 2024 and is expected to reach USD 150 billion in 2025. India’s bio-economy is projected to reach USD 1 trillion by 2047. India has approximately 4 percent of the global biotech market, produces 65 percent of WHO’s vaccine requirements, and has a 20 percent global biosimilar development pipeline.
Q: What is the Biopharma SHAKTI initiative?
A: The Biopharma SHAKTI initiative is a Government of India program aimed at launching 100 biologics by 2047 and strengthening India’s global leadership in biologics, biosimilars, innovation, and advanced healthcare manufacturing. The initiative complements India’s existing biotechnology support through the Department of Biotechnology, BIRAC, and the 12 DBT-supported biotechnology parks and 73 bio-incubators operating across the country.
Q: What are biosimilars and why is India leading globally?
A: Biosimilars are biologic medicines approved as highly similar to already-approved reference biologic drugs, with no meaningful differences in safety, purity, and potency. India leads globally in biosimilar development with approximately 20 percent of the global biosimilar pipeline, driven by companies like Biocon Biologics, Dr. Reddy’s, and Zydus Lifesciences. India’s cost advantage in bioprocess manufacturing, large pool of life science talent, and established regulatory track record with USFDA and EMA enable Indian companies to develop and manufacture biosimilars at substantially lower cost than Western competitors.
Q: What careers are available at top biotech companies in India?
A: Top biotech companies in India hire for R&D roles including Research Scientists, Analytical Chemists, and Biologics Engineers, as well as regulatory affairs specialists for global submissions, clinical research associates and trial coordinators, quality assurance and quality control professionals, manufacturing engineers specialising in bioprocessing and GMP operations, and data scientists supporting computational drug discovery. Serum Institute, Biocon, and Bharat Biotech are the most recognised hiring destinations and offer competitive compensation packages for life science professionals.
